Maine SUD Learning Community Newsletter |
|
|
|
Rachel Solotaroff, MD, MCR, FACP |
Interview with Rachel Solotaroff, MD, MCR, FACP, Penobscot Community Health Care’s (PCHC) new Executive Clinical Director of Behavioral Medicine and Community Wellness. Dr. Solotaroff joins PCHC having previously served as the President and CEO of Central City Concern in Portland, Oregon, an agency providing healthcare, housing, and employment services.
|
|
|
|
|
|
Reflection on Peer Support Workers
|
|
Peer Support Workers (PSWs) are people who have personally navigated mental health and/or substance use challenges and offer support to those who are currently struggling with those challenges after receiving training (Chapman et al., 2018; Chinman et al, 2017; Gagne et al., 2018; Johnson et al., 2014). PSWs can promote improved client outcomes, such as increased community engagement, reduction in hospitalizations, improved quality of life, and improved social functioning (Firmin et al., 2019; Moll et al., 2009; Rebeiro Gruhl et al., 2016). Across MaineHealth, Randy oversees over 50 Peer Support Workers, half of whom work in integrated teams within primary care, case management, and substance use treatment, and others who work within Peer Support Centers and emergency rooms. According to the Substance Abuse & Mental Health Services Administration (SAMHSA), a core feature of this type of care work includes the sharing of lived experience to offer knowledge and skills to others who are navigating their recovery journey (Mead et al., 2001; SAMSA, 2012). PSWs do not focus on telling people what they “should” do in their recovery journey; instead, they focus on the sharing of ideas and possibilities to benefit both people in the peer support relationship (Mead et al., 2001). This support is founded on the concepts of respect, shared responsibility, and mutual agreement on what is helpful for both people who are navigating their recovery (Mead et al., 2001).
|
|
|
To hear more from Randy and the experience of integrating peers into services, please listen or watch his discussions with the ME SUD Learning Community
For more information on Peer Support, visit:
|
|
FREQUENTLY ASKED QUESTIONS |
|
Where can I find the one-hour training to treat up to 30 patients with buprenorphine as an alternative to the current X-waiver training requirements? |
|
For questions like this or requests for training or assistance, please visit the MESUD Learning Community website to submit a request.
|
|
|
|
Sarah Siegel
I grew up on a tiny island called Cliff, off the coast of Portland in Casco Bay. A great deal of my childhood was steeped in the magnificent beauty that Maine’s wild places offer. I enjoyed nature, fishing and playing with my beloved cat, Lady.
I started drinking alcohol at age 9 to dull constant psychological and emotional pain, even though I had no idea at the time where it came from. However, it’s clear now looking back, that I hated myself for most of my life. I felt painfully out of place...
|
|
|
The third Wednesday of the month, 12pm to 1pm, 11/16/22 through 4/19/23 |
|
Audience: Prescribers and their team members from practices located in Maine who seek support to develop, implement, improve, and sustain OUD/SUD treatment for adolescents and young adults in Maine.
|
|
Learning Objectives:
- Bolster skills to respond to adolescent and young adult LBGTQ+ populations;
- Build competencies to deliver trauma-informed SUD/MOUD care;
- Work within family systems of care;
- Build basic knowledge on induction of buprenorphine with adolescents and young adults;
- Expand treatment of youth and young adult cannabis use disorder with n-acetylcysteine for those with and without OUD
|
|
Topics:
•Trauma-informed approaches for OUD/SUDs
•Stimulant use (prescription & other) and other concurrent substance use
•Induction and stabilization of buprenorphine in adolescents
•Treating youth within family systems
•How youth differ from adults
•LBTQ+ youth & diversity with SUD/OUD treatment
•Cannabis treatment with n-acetylcysteine with and without opioid
+ more
|
|
- Adrienne W. Carmack, MD, Medical Director, Office of Child and Family Services
- Jon Fanburg, MD, MaineHealth
- Ben Strick, LCSW, Spurwink
|
|
- Opioid Response Network (ORN) adolescent addiction prescriber consultants
- Eric Haram, LADC, Haram Consulting, LLC
- Amy West, FNP, PCHC, Bridge Clinic
|
|
Opioid Prescribing: Schedule an Individual Academic Detailing Session
The Maine Independent Clinical Information Service (MICIS) offers one-hour interactive sessions for medication prescribers. An Academic Detailing session is for a single prescriber and is individualized to a prescriber’s learning needs.
Schedule a session with an Academic Detailer online or at your practice location at no cost. MICIS currently offers 4 topics on opioid prescribing and a module on Hepatitis C:
- Opioid prescribing discussion, including Maine law
- MOUD (Medications for Opioid Use Disorder Treatment) Basics & Advanced Discussions
- Deprescribing opioids and benzodiazepines
- Simplified Treatment of Hepatitis C in Primary Care Settings
-
Academic Detailing topics
In addition to Academic Detailing, MICIS also offers one-hour education outreach presentations for medical practices, hospitals, and medical meetings.
|
|
|
Webinar | October 11 | 4-5 pm
Audience: Prescribing clinicians and their teams
Many patients can receive treatment for alcohol withdrawal safely in the community with the support of a primary care provider. This program will provide an overview of key elements and safety considerations of ambulatory alcohol withdrawal management programs.
Objectives:
- Describe the role of ambulatory alcohol withdrawal management in the ASAM continuum of care.
- Name 4 essential components of an ambulatory alcohol withdrawal management program.
- Outline advantages and disadvantages of using benzodiazepines for ambulatory alcohol withdrawal management.
|
|
Webinar | November 10 | 4-5:30 pm
Diagnosis and treatment of adult ADHD are on the rise. Patients with substance use disorder are thought to be disproportionately affected by ADHD but how safe is it, and what impact does the pharmacologic treatment have? This session will bring together psychiatry and addiction medicine physicians to explore this clinical question. We will present clinical advice about diagnosis, review literature about pharmacologic treatment, and bring experience and evidence together to discuss common clinical questions on this topic.
Objectives
- Identify considerations in enhancing the specificity of making an ADHD dx in adults
- Outline potential harms of stimulant therapy
- Describe the evidence for benefit of treatment of adult ADHD and the limitations of that evidence
Outcomes
- Identify considerations in enhancing the specificity of making an ADHD dx in adults
- Outline potential harms of stimulant therapy
- Describe the evidence for benefit of treatment of adult ADHD and the limitations of that evidence
|
|
Please visit the ME SUD Learning Community website for upcoming Events and Resources. |
|
|
|
|
|
|
|
